EXAS AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
EXAS Current Performance
-6.33%
Exact sciences corporation
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to EXAS
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
VCYT | Veracyte inc | 4 | 3 | 2 | 3 | 1 | |
TXG | 10x genomics inc | 1 | 3 | 4 | 3 | 1 | |
ADPT | Adaptive biotechnologies corp | 4 | 5 | 2 | 1 | 1 | |
PACB | Pacific biosciences of california inc | 2 | 3 | 2 | 2 | 1 | |
DNA | Ginkgo bioworks holdings inc | 2 | 3 | 4 | 3 | 1 |
- VCYT Veracyte incValue 4Trend 3Swing Trading 2Whale Interest 3Dividend 1See more
EXAS Profile
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company's products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company's flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient's breast tumor tissue.